CoChat

Effects of Differing Antecedent Increases of Plasma Cortisol on Counterregulatory Responses During Subsequent Exercise in Type 1 Diabetes

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Antecedent hypoglycemia can blunt neuroendocrine and autonomic nervous system responses to next-day exercise in type 1 diabetes. The aim of this study was to determine whether antecedent increase of plasma cortisol is a mechanism responsible for this finding. RESEARCH DESIGN AND METHODS: For this study, 22 type 1 diabetic subjects (11 men and 11 women, age 27 ± 2 years, BMI 24 ± 1 kg/m2, A1C 7.9 ± 0.2%) underwent four separate randomized 2-day protocols, with overnight normalization of blood glucose. Day 1 consisted of morning and afternoon 2-h hyperinsulinemic- (9 pmol · kg−1 · min−1) euglycemic clamps (5.1 mmol/l), hypoglycemic clamps (2.9 mmol/l), or euglycemic clamps with a physiologic low-dose intravenous infusion of cortisol to reproduce levels found during hypoglycemia or a high-dose infusion, which resulted in further twofold greater elevations of plasma cortisol. Day 2 consisted of 90-min euglycemic cycling exercise at 50% Vo2max. RESULTS: During exercise, glucose levels were equivalently clamped at 5.1 ± 0.1 mmol/l and insulin was allowed to fall to similar levels. Glucagon, growth hormone, epinephrine, norepinephrine, and pancreatic polypeptide responses during day 2 exercise were significantly blunted following antecedent hypoglycemia, low- and high-dose cortisol, compared with antecedent euglycemia. Endogenous glucose production and lipolysis were also significantly reduced following day 1 low- and high-dose cortisol. CONCLUSIONS: Antecedent physiologic increases in cortisol (equivalent to levels occurring during hypoglycemia) resulted in blunted neuroendocrine, autonomic nervous system, and metabolic counterregulatory responses during subsequent exercise in subjects with type 1 diabetes. These data suggest that prior elevations of cortisol may play a role in the development of exercise-related counterregulatory failure in those with type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-0382

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Plasma glucose (A) and insulin (B) concentrations (means ± SE) during day 2 euglycemic exercise studies in 22 patients (11 men/11 women) with type 1 diabetes. On the previous day, patients had undergone two 120-min euglycemic clamps (●, anteEugly), hypoglycemic clamps (■, anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (▲, anteCort1) or 2 μg · kg−1 · min−1 (▼, anteCort2) on day 1. Plasma glucose and insulin levels were comparable among the four experimental groups during basal and exercise periods.
FIG. 1. Plasma glucose (A) and insulin (B) concentrations (means ± SE) during day 2 euglycemic exercise studies in 22 patients (11 men/11 women) with type 1 diabetes. On the previous day, patients had undergone two 120-min euglycemic clamps (●, anteEugly), hypoglycemic clamps (■, anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (▲, anteCort1) or 2 μg · kg−1 · min−1 (▼, anteCort2) on day 1. Plasma glucose and insulin levels were comparable among the four experimental groups during basal and exercise periods.CC BY-NC-ND · PubMed Central
FIG. 2. Average plasma glucagon (A), growth hormone (B), pancreatic polypeptide (C), and cortisol (D) levels (means ± SE) during the final 30 min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (anteCort1) or 2 μg · kg−1 · min−1 (anteCort2) on day 1. There were significantly fewer increments of glucagon, growth hormone, and pancreatic polypeptide during the final 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *P < 0.05.
FIG. 2. Average plasma glucagon (A), growth hormone (B), pancreatic polypeptide (C), and cortisol (D) levels (means ± SE) during the final 30 min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (anteCort1) or 2 μg · kg−1 · min−1 (anteCort2) on day 1. There were significantly fewer increments of glucagon, growth hormone, and pancreatic polypeptide during the final 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 3. Plasma epinephrine (A) and norepinephrine (B) levels (means ± SE) during the final 30 min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (anteCort1) or 2 μg · kg−1 · min−1 (anteCort2) on day 1. There were significantly fewer increases of epinephrine and norepinephrine during the final 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *P < 0.05.
FIG. 3. Plasma epinephrine (A) and norepinephrine (B) levels (means ± SE) during the final 30 min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (anteCort1) or 2 μg · kg−1 · min−1 (anteCort2) on day 1. There were significantly fewer increases of epinephrine and norepinephrine during the final 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 4. Glucose kinetics (means ± SE) during the final 30 min of day 2 exercises in 22 type 1 diabetic patients (11 men/11 women). A: Glucose infusion rate. B: Glucose utilization. C: EGP. On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps, or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (anteCort1) or 2 μg · kg−1 · min−1 (anteCort2) on day 1. *P < 0.05 versus anteEugly.
FIG. 4. Glucose kinetics (means ± SE) during the final 30 min of day 2 exercises in 22 type 1 diabetic patients (11 men/11 women). A: Glucose infusion rate. B: Glucose utilization. C: EGP. On the previous day, patients had undergone two 120-min euglycemic clamps (anteEugly), hypoglycemic clamps, or euglycemic clamps with intravenous cortisol infusions at 1 μg · kg−1 · min−1 (anteCort1) or 2 μg · kg−1 · min−1 (anteCort2) on day 1. *P < 0.05 versus anteEugly.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Wasserman, 1984, The anaerobic threshold measurement to evaluate exercise performance, Am Rev Resp Dis, 129, 535

Cited by

Metadata

Authors
Bao, S., Briscoe, V. J., Tate, D. B., & Davis, S. N.
Affiliations
  • Vanderbilt University Medical Center (US)
  • United States Department of Veterans Affairs (US)
Corresponding author
Davis, Stephen N.
Venue
Diabetes
Published
2009-06-09
Volume
58
Issue
9
Pages
2100-2108
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2122856096
Cited by
19
References
51
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2020: 2 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 3 · 2012: 1
FWCI
1.46
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Vanderbilt University
  • National Institute for Health and Care Research
  • National Institutes of Health (5p60dk020593-31)
  • National Heart, Lung, and Blood Institute (P01HL056693, HL056693)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK020593, DK 20593, R01DK069803, P30DK079637, DK069803, P30DK020593)
  • National Center for Research Resources (M01RR000095, RR00095)
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
type 1 diabetes, plasma cortisol, counterregulatory response, physical activity, glucagon, growth hormone, epinephrine, norepinephrine, pancreatic polypeptide, endogenous glucose production, lipolysis, autonomic nervous system, neuroendocrine response
MeSH terms
Adult, Autonomic Nervous System, Blood Glucose, Diabetes Mellitus, Type 1, Epinephrine, Female, Humans, Hydrocortisone, Hyperinsulinism, Hypoglycemia, Infusions, Intravenous, Insulin, Male, Glucose Clamp Technique, Exercise

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.